This trial was conducted with DCA 6.25 mg/kg orally twice daily in previously treated stage IIIB/IV NSCLC or stage IV breast cancer. Growth inhibition by DCA was also evaluated in a panel of 54 NSCLC cell lines with and without cytotoxic chemotherapeutics (cisplatin and docetaxel) in normoxic and hypoxic conditions. Results and conclusions Under normoxic conditions in vitro, single-agent IC 50 was >2 mM for all evaluated cell lines. Synergy with cisplatin was seen in some cell lines under hypoxic conditions. In the clinical trial, after seven patients were enrolled, the study was closed based on safety concerns. The only breast cancer patient had stable disease after 8 weeks, quickly followed by progression in the brain. Two patients withdrew consent within a week of enrollment. Two patients had disease progression prior to the first scheduled scans. Within 1 week of initiating DCA, one patient died suddenly of unknown cause and one experienced a fatal pulmonary embolism. We conclude that patients with previously treated advanced NSCLC did not benefit from oral DCA. In the absence of a larger controlled trial, firm conclusions regarding the association between these adverse events and DCA are unclear. Further development of DCA should be in patients with longer life expectancy, in whom sustained therapeutic levels can be achieved, and potentially in combination with cisplatin.
in 2030 (World Health Organization Cancer Fact Sheet 2012) . In the United States, lung cancer is the leading cause of cancer-related death, in both men and women, with an estimated 160,340 deaths in 2012 (Howlader et al. 1975) . Most lung cancer cases are non-small cell lung cancer (NSCLC), which comprise over 85 % of all lung cancers diagnosed in the United States (Howlader et al. 2012) . Breast cancer remains the second leading cause of cancer-related death in American women with an estimated 39,510 deaths for 2012 (Howlader et al. 2012) . Therefore, the development of new treatment strategies is essential to improve outcomes for patients with metastatic breast cancer and advanced NSCLC.
Breast cancer and NSCLC, along with many other cancers, share a common aberration in cellular metabolism (Spira and Ettinger 2004; Warburg 1956; Feuerecker et al. 2012) . In normal cells, energy production from glucose most commonly occurs via oxidative phosphorylation in the mitochondria, a highly efficient pathway for energy production, providing up to 36 ATPs from one glucose molecule (Mathews et al. 2000a ). Cancer cells, however, exhibit elevated glucose uptake and preferentially produce energy via increased fermentation in the cytoplasm, which occurs at a more rapid rate but produces only 2 ATPs per glucose molecule (Warburg 1956; Mathews et al. 2000b; Vander Heiden 2009) . Cancer cells may rely on this increased glycolytic pathway flux to provide more biosynthetic precursors important for macromolecule biosynthesis and cell growth (Vander Heiden 2009 ). This high glycolytic activity observed in cancer cells is known as the Warburg effect (Warburg 1956 ).
Many studies have found that mutations in oncogenes and tumor suppressor genes promote the Warburg effect (Elstrom et al. 2004; Buzzai et al. 2005; Bensaad et al. 2006; Hu et al. 2012; Ying et al. 2012) ; however, cellular adaptation to hypoxic environments likely also contributes to this phenomenon in vivo (Gatenby and Gillies 2004) . Premalignant lesions develop in a microenvironment that is low in oxygen (Gatenby and Gillies 2004) . Cells which survive in hypoxic settings continue to multiply, and continued growth brings dividing cells further away from the oxygen source, increasing this selective pressure (Gatenby and Gillies 2004) . Increased level of hypoxia-inducible factor-1α (HIF-1α), a ubiquitously expressed oxygen-sensitive transcription factor that triggers multiple responses to hypoxic conditions, is one adaptive mechanism used by premalignancies (Gatenby and Gillies 2004; Loscalzo 2010) . HIF-1α increases the expression of pyruvate dehydrogenase kinase (PDHK) (Ke and Costa 2006; Dakubo 2010) , which inhibits pyruvate dehydrogenase (PDH), thereby inhibiting the conversion of pyruvate to acetyl-CoA, the substrate oxidized in the mitochondrial TCA cycle to produce ATP via the electron transport chain (Mathews et al. 2000a, b) . Therefore, in hypoxic environments, PDH (the gatekeeper of mitochondrial glucose oxidation) activity is inhibited, glucose metabolism shifts from oxidative phosphorylation in the mitochondria to fermentation in the cytoplasm, and glycolytic activity is increased to maintain sufficient ATP production via the quicker but less efficient an aerobic glycolysis (Mathews et al. 2000a, b; Dakubo 2010) . This metabolic adaptation leads to the suppression of apoptosis, providing a proliferative advantage in cancer cells (Remillard and Yuan 2004; Bonnet et al. 2007; Ruckenstuhl et al. 2009 ).
Switching of energy metabolism in cancer cells to oxidative phosphorylation can promote apoptosis and increase sensitivity to chemotherapy and radiation (Brahimi-Horn et al. 2012; Aykin-Burns et al. 2011 ). This switch can be accomplished by activating PDH (Mathews et al. 2000a, b) , which results in increases in the following: pyruvate entry to the mitochondria, acetyl-CoA levels, TCA cycle activity, and reactive oxygen species (ROS) production.
Dichloroacetate is a small compound with good oral bioavailability that promotes a metabolic shift from cytoplasmic glycolysis to mitochondrial oxidative phosphorylation by inhibiting PDHK (Sutendra et al. 2013; Kluza et al. 2012; Ayyanathan et al. 2012; Michelakis et al. 2010) . DCA has been used for over 25 years to treat children and adults with mitochondrial disorders. It has shown relatively modest toxicities, mostly limited to neurotoxicity (non-demyelinating, dose-dependent, and reversible peripheral neuropathy after prolonged use) (Pfeffer et al. 2012) . Several preclinical studies have successfully demonstrated DCA's anti-tumor activity (Kluza et al. 2012; Ayyanathan et al. 2012; Morfouace et al. 2012; Saed et al. 2011; Fiebiger et al. 2011) . A recent clinical trial performed at the University of Alberta found that DCA (6.25 mg/kg po bid) could be administered safely and effectively after debulking surgery, temozolamide, and radiation in the management of glioblastoma multiforme (GBM) (Michelakis et al. 2010) . DCA achieves 100 % bioavailability with excellent central nervous system (CNS) penetration, increasing its potential in cancers involving the CNS (Sutendra et al. 2013; Ayyanathan et al. 2012; Michelakis et al. 2010 ). The half-life of DCA after an oral dose is under an hour, but there is evidence that DCA inhibits its own metabolism, leading to sustained trough levels in the low mM range. We designed this phase II clinical trial to determine the response rate of oral dichloroacetate in patients with previously treated and/or metastatic breast cancer and NSCLC. In addition, we studied the effects of DCA across a panel of 54 NSCLC cell lines.
Patients, materials, and methods

Patients
Eligible patients were ≥18 years old with pathologically confirmed stage IV breast cancer or stage IIIB/IV NSCLC (by AJCC Staging 6th Edition) with radiographically measurable disease by RECIST 1.0 (Lichtenfeld 2012) . Eligible lung cancer patients either demonstrated disease progression despite receiving platinum-based chemotherapy, or refused recommended chemotherapy. Eligible metastatic breast cancer patients received prior anthracycline and taxane-based chemotherapy, hormonal therapy if the tumor was ER positive, and trastuzumab if immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH) demonstrated HER2 amplification. Patients were required to have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2 (this was changed to 0-1 during the course of the study) (Oken et al. 1982) . Life expectancy of at least 12 weeks, and adequate bone marrow, hepatic, and renal function were required. Ejection fractions were evaluated using multi-gated acquisition (MUGA) scan, and only those with normal ejection fractions were included in this study. Patients were excluded for peripheral neuropathy > grade 1 at the time of study initiation, pregnancy, other invasive cancers within the last 2 years (with the exception of non-melanoma skin cancer), cancer treatment within 28 days of first DCA dose (with the exception of palliative radiation to the bone and trastuzumab in HER2-positive patients), active CNS metastases, malabsorption syndromes, or medications that may interact with DCA.
This study was approved by the Institutional Review Board at the University of California Los Angeles (UCLA), and all patients provided written informed consent documentation prior to enrollment. The study was monitored by the Jonsson Comprehensive Cancer Center (JCCC) Data Safety and Monitoring Board (DSMB).
Study design
This single-arm, phase II, open-labeled study was designed to observe the role of oral DCA therapy in the management of stage IIIB/IV NSCLC and metastatic breast cancer. Twenty-nine patients were planned for the NSCLC cohort. As part of a Simon 2-stage design, the breast cancer cohort was to enroll 18 patients with expansion to 43 patients if 3 responses were seen among the first 18 patients. The primary end point was response rate. Secondary end points included safety/tolerability, progression-free survival (PFS), and overall survival (OS). The analysis described in the manuscript is descriptive based on the low number of patients enrolled.
Treatment
Based on the dosage data determined by a glioblastoma trial performed by Michelakis et al. in (2010) , as well as trials published with DCA as a therapy for patients with congenital mitochondria diseases (Stacpoole et al. 2006 ), a dose of 6.25 mg/kg orally twice daily was chosen. DCA was purchased from a commercial chemical supplier (TCI America, Eugene OR). Each dose was administered with food. Patients were continued on treatment until radiographic progression, clinical progression, unacceptable toxicity, withdrawal of consent, or death. One dose reduction to 3.25 mg/kg twice daily was allowed in the setting of grade ≥2 adverse events after resolution to grade ≤1.
Study assessments
Safety
Safety assessments occurred within 28 days of therapy and on day 1, 8 (added during the study), 15, 29, and every 28 days thereafter as well as at the end of study. Assessments included history and physical examination (including a focused neurological examination), vital signs, blood counts with differential, adverse events (AEs) graded according to NCI-CTCAE version 3.0, concomitant medications, and standard hematology and chemistry tests (Common Terminology Criteria for Adverse Events 2006). During the study, a requirement for a baseline MRI of the brain with contrast was added. CT scan of the chest and upper abdomen with contrast was required within 28 days of enrollment, and tumor response was evaluated radiographically using the RECIST 1.0 every 8 weeks. An optional PET scan was offered at baseline, after 14 days and 3 months of therapy.
Cell lines, cell cultures, and reagents Dichloroacetate, cisplatin, and docetaxel were studied in 54 NSCLC cell lines in vitro (Garon et al. 2013a ), all of which were obtained from American Type Culture Collection (ATCC, Manassas VA). Cell lines were as follows: A427, A549, Calu-1, Calu-3, Calu-6, H23, H226, H358, H441, H460, H520, H522, H596, H661, H810, H838, H1155, H1299, H1385, H1435, H1437, H1563, H1568, H1581, H1623, H1651, H1666, H1703, H1734, H1755, H1793, H1836, H1838, H1869, H1944, H1975, H2023, H2030, H2073, H2106, H2110, H2122, H2126, H2135, H2172, H2228, H2286, H2291, H2342, H2405, H2444, HCC-827, SHP-77, SK-LU-1.
A549 cells were cultured in tissue culture medium F12-K (ATCC) supplemented with 10 % heat-inactivated fetal bovine serum (FBS), 1 % penicillin G-streptomycinfungizone solution (PSF, Irvine Scientific, Santa Ana, CA). A427, Calu-6, Calu-3, and SK-LU-1 were grown in EMEM (ATCC) supplemented with 10 % heat-inactivated FBS and PSF. H1155, H1581, H1693, H1435, H1623, H1651, H1666, H2085, and H1869 were grown in ACL-4 supplemented with 10 % heat-inactivated FBS 5 g/L BSA, 0.02 % insulin, 0.01 mg/mL transferrin, 25 nM sodium selenite, 50 nM hydrocortisone, 1 ng/ml EGF, 0.01 mM ethanolamine, 0.01 mM O-phophorylethanolamine, 100 pM 3,3′,5-Triiodo-l-Thyronine (T3), 0.5 mM sodium pyruvate, 10 mM HEPES, and 2 mM l-glutamine. H2286, H2073, and H2405 were grown in complete ACL-4 with 2 mg/L BSA (instead of 5 g/L). H1793, H1836, H2342, H2106, H2023, H2126, H2135, and H810 were grown in HITES supplemented with 5 % heat-inactivated FBS. The remaining cell lines were cultured in RPMI 1640 (Cellgro, Manassas, VA) supplemented with 10 % heat-inactivated FBS, 2 mmol/L glutamine (Invitrogen, Carlsbad, CA), and PSF. For all cell lines reported, retesting by genomic DNA, with comparison to the ATCC database, occurred within a year of the described experiments.
In vitro proliferation assays
For single-agent experiments evaluating DCA, cisplatin, and docetaxel, cells were seeded in duplicate at 5,000-10,000 cells per well in a 24-well plate. On day 1, drug was added starting from 10 μM with twofold dilutions over 12 concentrations for all drugs except DCA, for which the starting concentration was 10 mM. Data were compared to untreated controls. Cells were counted using a Z1 Coulter Particle Counter (Beckman Coulter) on day 1 (only controls) and day 6 with percent growth inhibition defined as 100 × (1 − [generations in treated wells/generations in untreated controls]). Experiments were performed in duplicate. Error bars represent standard error for each experiment. Nonlinear curve fitting to data points was performed using the Proc NLIN function in SAS for Windows version 9.2 (SAS Institute, Inc., Cary, NC) using a basic four-parameter sigmoid model. IC 50 (concentration needed to prevent 50 % of cell population doublings) was interpolated from the resulting curves (Garon et al. 2013b ).
Measurement of oxygen consumption rates post-48-h DCA treatment Cellular oxygen consumption rates were measured in 4 cell lines using a water-jacketed (37 °C) anaerobic chamber fitted with a fiber-optic oxygen sensor (INSTECH Model 110 Optic Oxygen Monitor). The fiber-optic probe was calibrated with 15 mM sodium hydrosulfite (Sigma) corresponding to 0 % oxygen and cell culture media corresponding to 20.9 % oxygen.
In vitro combination proliferation assays
For combination in vitro proliferation assays, the same techniques were performed as described above, but on day 1, a combination of DCA and cisplatin or docetaxel starting at 2 μM with twofold dilutions over 6 concentrations was added. Combination indices were then calculated as described elsewhere (Calcusyn, Biosoft) (Chou 2010 ). This evaluation was performed under both normoxic and hypoxic conditions of 0.5 % oxygen, 5 % CO 2 using a c-chamber, and ProOx model C2 gas oxygen and CO 2 controller from BioSpherex.
Results
Patient characteristics
Seven patients (6 with NSCLC and 1 with breast cancer) were enrolled in this open-label, phase II clinical trial. All patients were previously treated, most with multiple previous therapies. A summary of patient demographics, tumor characteristics, and previous treatments received are summarized in Table 1 .
Clinical outcomes
Two patients died suddenly within 1 week of starting DCA, one from a fatal pulmonary embolism (PE) and the other of unknown cause, presumed to be a cerebrovascular accident based on the available medical information. The relation of these deaths to DCA was uncertain. The median number of days the patients stayed on the trial was 12 (range 4-72 days). The one breast cancer patient experienced stable disease for 2 months before developing brain metastases, and two patients experienced disease progression prior to their first set of scans (scheduled for 8 weeks). Two patients withdrew consent, one after experiencing a PE and the other to enroll in hospice care. Outcome data are summarized in Table 2 . Due to the lack of clinical benefit observed along with the two deaths, the JCCC DSMB closed the study.
Safety and tolerability
All patients experienced AEs, most low grade (Table 3) . The most frequent AEs were lower extremity edema and abdominal pain, both of which were seen in 3 patients. Grades ≥3 AEs were abdominal pain (1), lower extremity edema (1), elevated AST (1), pulmonary embolism (2), hyponatremia (1), volume depletion (1), and sudden death (1). Four out of the 7 patients experienced grade >3 AEs. No patients received a dose reduction, but 3 patients required dose delay for grade >2 AEs. There were two instances of grade 1 disequilibrium that were attributed to DCA and one seizure that was attributed to a new brain metastasis, but no other neurological AEs. Median # days on study 12 Sensitivity to DCA, cisplatin, and docetaxel in human NSCLC cell lines in vitro
We studied several well-characterized NSCLC cell lines in order to determine the in vitro effects of DCA by exposure to serial dilutions. In addition, we sought to determine the possibility of synergy with commonly used cytotoxic agents. Limited sensitivity was seen across the cell line panel with DCA, with no lines demonstrating an IC 50 < 2 mM (Fig. 1a) . Sensitivity of the cell lines to the standard chemotherapeutics cisplatin (Fig. 1b) and docetaxel (Fig. 1c) was determined, so that they could be evaluated as part of combination assays with DCA.
Oxygen consumption
We observed a trend toward increased oxygen consumption in cell lines treated with 5 mM DCA (Fig. 2) . This increase in oxygen consumption reached statistical significance (p = 0.005) for the A427 cell line after exposure to 5 mM DCA (Fig. 2d) .
Combination of DCA and cisplatin or docetaxel in selected cell lines
The in vitro response to DCA in combination with cisplatin and docetaxel was compared to cisplatin and docetaxel alone. Under normoxic conditions, DCA did not enhance the anti-proliferative action of cisplatin or docetaxel (data not shown). However, under hypoxic conditions, a condition that is known to induce the expression of DCA's target enzyme PDHK, the combination of DCA and cisplatin, showed evidence of synergy in two of the evaluated cell lines, A427 and HCC-827 (Fig. 3a, b) . The combination of DCA and cisplatin in SKLU-1 and A549 did not show evidence of synergy at relevant doses (Fig. 3c, d ). Experiments combining DCA and docetaxel did not demonstrate a synergistic effect (Fig. 4) . 
Discussion
Several preclinical studies and one recent clinical trial have suggested that DCA holds promise as a novel anticancer agent (Sutendra et al. 2013; Kluza et al. 2012; Michelakis et al. 2010; Morfouace et al. 2012; Saed et al. 2011; Fiebiger et al. 2011) . DCA has also received a fair amount of attention in the lay press (The DCA Site 2012). Its relatively favorable side effects and low cost make DCA an attractive consideration for patients, though definitive clinical data are lacking. Therefore, we designed this phase II trial to determine the response rate, safety, and tolerability of oral DCA in patients with metastatic breast cancer and advanced stage NSCLC. Our study demonstrated no clinical improvement in seven subjects with advanced stage cancers treated with DCA. The study was modified to address safety concerns at multiple time points, including amendments to include only patients with baseline ECOG 0 or 1, require a baseline MRI of the brain, and add an additional blood draw. The lack of a control arm makes it difficult to assess the expected frequency of AEs. However, the JCCC DSMB felt that the expected rate was exceeded and they terminated the study. The rate of AEs also exceeded what has been seen in our studies of similar populations (Garon et al. 2013b; Edelman et al. 2012) .
Oral DCA is rapidly and completely absorbed, but it is also rapidly cleared from the plasma, and repeated dosing is required to obtain sustained plasma levels (Curry et al. 1985) . The pharmacokinetic clearance of DCA increased as a function of DCA exposure in 20 healthy subjects (Curry et al. 1985; Jia et al. 2006 ). This pharmacokinetic profile may be in part due to DCA-mediated inhibition and decrease in the expression of GSTz1, the enzyme responsible for dehalogenation of DCA, an important step for its metabolism and excretion (Jia et al. 2006 ).
Michelakis et. al. examined the activity of DCA in five glioblastoma (GBM) patients, initially managed with surgery, radiation, and temozolomide, after 15 months of DCA therapy and demonstrated radiographic evidence of tumor regression in three of five patients (Michelakis et al. 2010 ). In the three responsive patients, tissue samples before and after DCA therapy all demonstrated decreased cell proliferation, increased apoptosis, and increased PDH activity (Michelakis et al. 2010) . However, therapeutic trough DCA levels were only achieved after several months of consistent dosing (Michelakis et al. 2010) . Thus, therapeutic DCA levels may not have been achieved in our patient population in time to prevent disease progression, suggesting that DCA may not be an ideal drug for cancers at risk of rapid progression.
In our in vitro analysis of the effect of DCA on NSCLC, significantly enhanced oxygen consumption was observed with 5 mM DCA in the A427 cell line. With respect to the anti-proliferative activity of DCA, no significant singleagent inhibition or synergistic activity with docetaxel or cisplatin under normoxic conditions was observed. However, we observed a trend toward enhanced growth inhibition when DCA was combined with cisplatin in two of four evaluated cell lines in hypoxic conditions, suggesting that DCA may be an effective agent when given with cisplatin under hypoxic conditions. Similar results have been seen when lung carcinoid cell lines are treated with platinum-based chemotherapy and DCA (Fiebiger et al. 2011) . A novel chimeric drug generated by combining two molecules of DCA with one of cisplatin (mitaplatin) showed clear synergism in terms of cell death in several cancer cell lines (Dhar and Lippard 2009) , including induction of apoptosis in cell lines resistant to cisplatin (Xue et al. 2012) .
The interest in DCA by the general public has led to unique issues in its development as an antineoplastic. Cancer patients have frequently gone to Web sites that have touted benefits of DCA that are not clearly supported by the medical literature. During the conduct of this trial, the investigators received countless calls and e-mails from cancer patients around the world requesting additional information on DCA. Since DCA is commercially available and accessible, patients can (and often have) obtained DCA for the treatment for cancer (The DCA Site 2012) . We received several calls from outside hospitals (who found our information on clinicaltrials.gov) inquiring about toxicity, particularly neurologic, of DCA. On further investigation, these patients were frequently self-administering doses that are larger than what has been shown to be safe in cancer patients. 
Conclusion
We acknowledge the difficulty in drawing solid conclusions about efficacy and safety of DCA in patients with advanced cancer, based on our data. However, we feel it is important to publish our experience and stress the danger of using DCA in patients with advanced and rapidly progressing disease, where DCA may not reach adequate drug levels to have the potential for therapeutic effect. Desperate and unfortunate patients may self-medicate with DCA given its wide availability on the Internet and the potential for exploitation by for-profit suppliers. Further studies should focus on DCA as a sensitizing agent in combination therapy, in patients with an expected meaningful survival of at least several months. 
